YU30902A - Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju - Google Patents

Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju

Info

Publication number
YU30902A
YU30902A YU30902A YUP30902A YU30902A YU 30902 A YU30902 A YU 30902A YU 30902 A YU30902 A YU 30902A YU P30902 A YUP30902 A YU P30902A YU 30902 A YU30902 A YU 30902A
Authority
YU
Yugoslavia
Prior art keywords
compounds
production
cyclopropanes
novel
medicaments containing
Prior art date
Application number
YU30902A
Other languages
English (en)
Inventor
Wolfgang Eberlein
Wolfhard Engel
Klaus Rudolf
Henri Doods
Gerhard Hallermayer
Eckhart Bauer
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Publication of YU30902A publication Critical patent/YU30902A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Pronalazak se odnosi na jedinjenja opšte formule (I), u kojoj su R i R1 definisanl kao u zahtevu (1), na njihiove tautomere, njihove dijastereomere, njihove enantiomere, njihove smeše i njihove soli, naročito njihove fiziološki podnošljive soli, sa neorganskim ili organskim kiselinama ili bazama, koja imaju dragocena farmakološka svoistva, naročito CGRP-antagonistička svojstva, na lekove koji sadrže ova jedinjenja, na njihovu primenu i na postupak za njihovo pripremanje.[The invention relates to compounds of the general formula (I), in which R and R1 are defined as in claim 1. The invention also relates to their tautomers, diastereomers and enantiomers, to mixtures thereof and to their salts, especially to their physiologically acceptable salts with inorganic or organic acids or bases. The inventive compounds have valuable pharmacological properties, including CGRP antagonist properties. The invention further relates to medicaments that contain said compounds, to the use and the production thereof.
YU30902A 1999-10-29 2000-10-21 Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju YU30902A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19952147A DE19952147A1 (de) 1999-10-29 1999-10-29 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
YU30902A true YU30902A (sh) 2005-07-19

Family

ID=7927315

Family Applications (1)

Application Number Title Priority Date Filing Date
YU30902A YU30902A (sh) 1999-10-29 2000-10-21 Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju

Country Status (27)

Country Link
US (2) US20030139417A1 (sh)
EP (1) EP1228059B1 (sh)
JP (1) JP3869721B2 (sh)
KR (1) KR20020047290A (sh)
CN (1) CN1177844C (sh)
AT (1) ATE301117T1 (sh)
AU (1) AU781856B2 (sh)
BG (1) BG106638A (sh)
BR (1) BR0015147A (sh)
CA (1) CA2387134C (sh)
CZ (1) CZ20021812A3 (sh)
DE (2) DE19952147A1 (sh)
EA (1) EA005137B1 (sh)
EE (1) EE200200220A (sh)
HK (1) HK1051858A1 (sh)
HR (1) HRP20020373A2 (sh)
HU (1) HUP0203496A3 (sh)
IL (1) IL148975A0 (sh)
MX (1) MXPA02004119A (sh)
NO (1) NO20021799D0 (sh)
NZ (1) NZ518698A (sh)
PL (1) PL354715A1 (sh)
SK (1) SK7282002A3 (sh)
TR (1) TR200201168T2 (sh)
WO (1) WO2001032648A1 (sh)
YU (1) YU30902A (sh)
ZA (1) ZA200203256B (sh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100558728C (zh) * 2002-06-05 2009-11-11 布里斯托尔-迈尔斯斯奎布公司 降钙素基因相关肽受体拮抗剂
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
BR0318637A (pt) 2003-12-05 2007-02-13 Bristol Myers Squibb Co antagonistas de receptores de peptìdios relacionados com o gene de calcitonina
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
AU2005285292B2 (en) * 2004-09-09 2011-03-10 Merck Sharp & Dohme Corp. Aryl spirolactam CGRP receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
JP2009515972A (ja) * 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロラクタムアリールｃｇｒｐ受容体アンタゴニスト
WO2009034029A2 (de) * 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
AU2008313733A1 (en) 2007-10-18 2009-04-23 Boehringer Ingelheim International Gmbh CGRP antagonists
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2013151707A1 (en) 2012-04-05 2013-10-10 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP3049077A4 (en) 2013-09-26 2017-02-15 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP6449893B2 (ja) 2013-09-26 2019-01-09 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法
JP2019040859A (ja) * 2017-08-22 2019-03-14 株式会社エンプラス 発光装置、面光源装置および光束制御部材
CN114957145B (zh) * 2022-04-14 2023-07-18 浙江师范大学 一种1,2,4-苯并三嗪衍生物及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655667A (en) * 1968-04-04 1972-04-11 Smith Kline French Lab 1-(2-benzoylcyclopropylmethyl)-4-phenylpiperazines
US3873707A (en) * 1972-10-02 1975-03-25 Robins Co Inc A H 1-Cyclopropyl-3-mono-(and 2,3-di) substituted-1-propanones in compositions and method for treating pain
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
AU704825B2 (en) 1995-12-15 1999-05-06 Novo Nordisk A/S Novel method
EP0934068A1 (en) * 1996-09-09 1999-08-11 Smithkline Beecham Corporation Compounds and methods
TR199900537T2 (xx) 1996-09-10 1999-07-21 Dr. Karl Thomae Gmbh D�n��t�r�lm�� amino asitler, bunlar� i�eren farmas�tik preparatlar.
BR9809147A (pt) 1997-05-22 2000-08-01 Searle & Co Composto pirazol substituìdo, composição farmacêutica, processos para tratar um distúrbio mediado por tnf, um distúrbio mediado por quinase p38, inflamação e artrite, e, para preparar pirazóis
JP2002506863A (ja) * 1998-03-17 2002-03-05 ノボ ノルディスク アクティーゼルスカブ 新規ヘテロ環式化合物
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2002540204A (ja) * 1999-03-26 2002-11-26 アストラゼネカ・アクチエボラーグ 新規化合物
DE19937304C2 (de) 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US6696418B1 (en) * 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
MXPA03004652A (es) * 2000-12-21 2003-09-05 Warner Lambert Co Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato.
US20030191110A1 (en) * 2001-11-01 2003-10-09 Martyn Botfield Modulators of the cholesterol biosynthetic pathway
US6977265B2 (en) * 2001-11-30 2005-12-20 Roche Palo Alto Llc Piperidine CCR-3 receptor antagonists
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof

Also Published As

Publication number Publication date
CA2387134A1 (en) 2001-05-10
US7407963B2 (en) 2008-08-05
EE200200220A (et) 2003-06-16
WO2001032648A1 (de) 2001-05-10
BR0015147A (pt) 2002-07-16
ZA200203256B (en) 2003-04-10
CA2387134C (en) 2008-07-08
CN1177844C (zh) 2004-12-01
HRP20020373A2 (en) 2003-10-31
MXPA02004119A (es) 2003-10-06
EP1228059B1 (de) 2005-08-03
NO20021799L (no) 2002-04-17
EA005137B1 (ru) 2004-12-30
EA200200447A1 (ru) 2002-10-31
EP1228059A1 (de) 2002-08-07
CN1387526A (zh) 2002-12-25
PL354715A1 (en) 2004-02-09
HUP0203496A3 (en) 2004-01-28
NO20021799D0 (no) 2002-04-17
CZ20021812A3 (cs) 2002-08-14
BG106638A (bg) 2003-01-31
AU7921300A (en) 2001-05-14
DE50010886D1 (de) 2005-09-08
AU781856B2 (en) 2005-06-16
TR200201168T2 (tr) 2002-08-21
DE19952147A1 (de) 2001-05-03
JP3869721B2 (ja) 2007-01-17
JP2003513087A (ja) 2003-04-08
ATE301117T1 (de) 2005-08-15
KR20020047290A (ko) 2002-06-21
IL148975A0 (en) 2002-11-10
HK1051858A1 (en) 2003-08-22
HUP0203496A2 (hu) 2003-02-28
US20030139417A1 (en) 2003-07-24
SK7282002A3 (en) 2002-11-06
NZ518698A (en) 2004-12-24
US20050267137A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
YU30902A (sh) Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
MXPA05004188A (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion, asi como su empleo como medicamentos.
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
WO2009065919A3 (de) Organische verbindungen
TW200504032A (en) New carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
YU50002A (sh) Supstituisani piperidini, lekovi koji sadrže ova jedinjenja i postupci za njihovu proizvodnju
MX9803954A (es) Derivados de aminoacidos, composiciones farmaceuticas que contienen estos compuestos y procesos para prepararlos.
ES2139760T3 (es) Nuevas lactamas sustituidas con 4-piperidinilo con propiedades antagonistas del receptor de neurokinina 2 en el tratamiento del asma.
CA2337825A1 (en) Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist
NO20001483L (no) Nye NPY-agonister
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
MX2010003849A (es) Antagonistas de cgrp.
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
DK0733051T3 (da) Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
WO2003066594A3 (de) 3-alkanoylamino-propionsäure-derivate als inhibitoren des integrins avss6
WO1999062893A3 (de) Neue neurokininantagonisten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
WO2006100026A8 (de) 2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl-piperidine als cgrp-antagonisten
FI935799A (fi) Aryylisubstituoituja heterosyklisiä yhdisteitä
DK0604355T3 (da) Arylsubstituerede heterocykliske forbindelser